{Reference Type}: Journal Article
{Title}: KPNB1-mediated nuclear import in cancer.
{Author}: Shi Q;Lin M;Cheng X;Zhang Z;Deng S;Lang K;Yang Z;Sun X;
{Journal}: Eur J Pharmacol
{Volume}: 955
{Issue}: 0
{Year}: 2023 Sep 15
{Factor}: 5.195
{DOI}: 10.1016/j.ejphar.2023.175925
{Abstract}: Dysregulation of nucleocytoplasmic shuttling impairs cellular homeostasis and promotes cancer development. KPNB1 is a member of karyopherin β family, mediating the transportation of proteins from the cytoplasm to the nucleus. In a variety of cancers, the expression of KPNB1 is upregulated to facilitate tumor growth and progression. Both downregulation of KPNB1 level and inhibition of KPNB1 activity prevent the entry of cancer-related transcription factors into the nucleus, subsequently suppressing the proliferation and metastasis of cancer cells. Currently, five KPNB1 inhibitors have been reported and exhibited good efficacy against cancer. This paper provides an overview of the role and mechanism of KPNB1 in different cancers and KPNB1-targeted anticancer compounds which hold promise for the future.